Answers are grounded in this paper and cite their sources.
Shows enhanced bone marrow-to-brain signaling improves blood flow and cognition in Alzheimer's, suggesting new interventions.
Patients with Alzheimer's disease (AD) often develop osteoporosis, but the role of bone remodeling in AD remains unclear. We previously showed that osteoblast‐specific expression of APP swe induces bone loss, glial activation, and behavioral deficits, suggesting a bone‐to‐brain signaling axis. Here, we identify an altered skull bone marrow (SBM)‐to‐brain axis in AD. Early SBM changes, including reduced cellularity, increased density, and expanded vascular channels to the meninges, occur in multiple APP swe mouse models. These vascular changes facilitate migration of SBM‐derived myeloid cells into the meninges and cortex, improving cerebral blood flow (CBF) and slowing cognitive decline. Notably, these effects are age‐dependent, emerging at 6 months but diminishing by 12 months. Enhancing this axis via bone marrow transplantation improves CBF and cognitive function in aged mice, whereas disrupting it through osteoblastic deletion of ATP6AP2 impairs both. Together, these findings reveal a previously unrecognized SBM‐to‐brain axis that regulates immune, vascular, and cognitive functions, highlighting systemic contributions to AD pathogenesis.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: